1. Home
  2. GPRO vs CBIO Comparison

GPRO vs CBIO Comparison

Compare GPRO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPRO
  • CBIO
  • Stock Information
  • Founded
  • GPRO 2004
  • CBIO 2003
  • Country
  • GPRO United States
  • CBIO United States
  • Employees
  • GPRO N/A
  • CBIO N/A
  • Industry
  • GPRO Industrial Machinery/Components
  • CBIO
  • Sector
  • GPRO Consumer Discretionary
  • CBIO
  • Exchange
  • GPRO Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • GPRO 194.6M
  • CBIO 173.5M
  • IPO Year
  • GPRO 2014
  • CBIO N/A
  • Fundamental
  • Price
  • GPRO $2.06
  • CBIO $10.39
  • Analyst Decision
  • GPRO
  • CBIO Strong Buy
  • Analyst Count
  • GPRO 0
  • CBIO 5
  • Target Price
  • GPRO N/A
  • CBIO $25.60
  • AVG Volume (30 Days)
  • GPRO 11.4M
  • CBIO 133.4K
  • Earning Date
  • GPRO 11-06-2025
  • CBIO 11-23-2025
  • Dividend Yield
  • GPRO N/A
  • CBIO N/A
  • EPS Growth
  • GPRO N/A
  • CBIO N/A
  • EPS
  • GPRO N/A
  • CBIO N/A
  • Revenue
  • GPRO $746,731,000.00
  • CBIO N/A
  • Revenue This Year
  • GPRO N/A
  • CBIO N/A
  • Revenue Next Year
  • GPRO $9.72
  • CBIO N/A
  • P/E Ratio
  • GPRO N/A
  • CBIO N/A
  • Revenue Growth
  • GPRO N/A
  • CBIO N/A
  • 52 Week Low
  • GPRO $0.40
  • CBIO $9.81
  • 52 Week High
  • GPRO $3.05
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • GPRO 50.47
  • CBIO 32.73
  • Support Level
  • GPRO $1.95
  • CBIO $10.96
  • Resistance Level
  • GPRO $2.53
  • CBIO $12.27
  • Average True Range (ATR)
  • GPRO 0.22
  • CBIO 0.78
  • MACD
  • GPRO -0.06
  • CBIO -0.15
  • Stochastic Oscillator
  • GPRO 27.05
  • CBIO 16.83

About GPRO GoPro Inc.

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: